Full-Time

Senior Analyst/Manager

Commercial Analytics & Forecasting

Confirmed live in the last 24 hours

Acadia Pharmaceuticals

Acadia Pharmaceuticals

501-1,000 employees

Develops treatments for neuro-psychiatric disorders

Compensation Overview

$97k - $121.4k/yr

+ Discretionary Bonus + Equity Awards

Mid, Senior

Princeton, NJ, USA + 1 more

More locations: San Diego, CA, USA

Hybrid model requires this role to work in the office on average three days per week.

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in business administration, marketing, finance, or a related field; MS/MBA is a plus
  • Manager level requires 5+ years in Commercial or Sales Operations with at least 2 years’ experience in forecasting
  • Sr Analyst level requires 3+ years in Commercial or Sales Operations with at least 1 year in forecasting
  • Proven experience using various analytical and forecasting methodologies that leverage historical product demand, primary and secondary research insights, and team inputs to design, build, and maintain accurate forecasting models using MS Excel and/or other forecasting applications
  • A strong understanding of forecasting methodologies (including EPI and historical trend approaches) and quantitative techniques is needed to produce accurate product launch and in-line forecasts for the organization
  • Demonstrated advanced modeling skills using MS Excel, and/or forecasting/statistical modeling software, and reporting applications
  • Excellent analytical reasoning, financial acumen, and problem-solving capabilities with demonstrated abilities to think creatively and strategically to solve and answer key business questions/problems
Responsibilities
  • Responsible for supporting global forecasting efforts by working with commercial leadership (US, Canada and EU), brand/franchise leads, patient services and finance to develop multi-year monthly patient, unit, and revenue forecasts for products within the neuroscience or rare disease franchise, by leveraging historical product performance trends, the primary/secondary market insights, and soliciting team inputs
  • Responsible for providing demand (patients on product, shipments, & units) and revenue estimates and projections for month-end, quarter-end, and year-end performance to commercial leadership, executive team, brand leads, finance, and investor relations groups
  • Design, build, and maintain accurate, actionable, evidence-based forecasting models and predictive methodologies/analytics
  • Identify and incorporate novel forecast approaches and methodologies to contribute to the advancement of the forecast function at Acadia
  • Maintain financial and manufacturing forecasts on a monthly cycle, and annually revise the long-range forecast, in partnership with Finance, Marketing, Manufacturing, and Managed Markets
  • Perform in-depth data analysis to build a robust assumptions library and forecast inputs
  • Monitor forecast accuracy and quantify the impact of assumption differences, and suggest corrective actions as appropriate
  • Present and defend the forecast approach, methodology, assumptions, and output to multiple levels of management
  • Collaborate with Commercial Analysis, Insights, and Operations peers on modeling, data, and market research needs, communicating issues, and responding to requests from senior leadership
  • Ensure all forecasting activities are conducted in accordance with financial and ethical compliance guidelines
  • Other responsibilities as assigned
Desired Qualifications
  • The ideal candidate will embody Acadia’s core values: we fight for patients, we are driven by innovation, we are family, we are determined, and we take our work seriously
Acadia Pharmaceuticals

Acadia Pharmaceuticals

View

Acadia Pharmaceuticals focuses on developing and providing treatments for patients with serious neurological and psychiatric conditions. The company has created the first FDA-approved medication specifically for managing hallucinations and delusions related to Parkinson’s disease psychosis, as well as the first approved treatment for Rett syndrome in the U.S. and Canada. Their products work by targeting the underlying symptoms of these conditions, helping to improve the quality of life for patients. What sets Acadia apart from its competitors is its dedicated focus on neuro-psychiatric and neuro-rare diseases, with ongoing clinical trials aimed at addressing conditions like Prader-Willi syndrome and Alzheimer’s disease psychosis. The goal of Acadia Pharmaceuticals is to provide effective solutions that enhance the well-being of patients and their families.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased focus on personalized medicine benefits Acadia's tailored CNS therapies.
  • FDA's supportive regulatory environment aids Acadia's innovative CNS disorder treatments.
  • Growing interest in rare diseases supports Acadia's Rett syndrome treatment efforts.

What critics are saying

  • Increased competition from Biogen and Roche may impact Acadia's market share.
  • Litigation risks from class action lawsuit could lead to financial liabilities.
  • Challenges in DAYBUE's market adoption and reimbursement negotiations may affect commercialization.

What makes Acadia Pharmaceuticals unique

  • Acadia focuses on CNS disorders with a strong pipeline including pimavanserin.
  • The company collaborates with Biovail and Stoke Therapeutics for innovative drug development.
  • Acadia's DAYBUE is a pioneering treatment for Rett syndrome in the U.S.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
ETF Daily News
Mar 27th, 2025
Cibc World Markets Corp Invests $206,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Cibc World Markets Corp invests $206,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Fierce Pharma
Dec 9th, 2024
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO).

MarketWatch
Nov 26th, 2024
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711

Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.

World Pharmaceuticals
Oct 17th, 2024
Acadia gets Health Canada approval for Daybue to treat Rett Syndrome

US-based biopharmaceutical company Acadia Pharmaceuticals has received Health Canada marketing authorisation for Daybue (trofinetide) to treat a rare genetic neurological disorder.

PRWeb
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."